Whales with a lot of money to spend have taken a noticeably bullish stance on Abbott Laboratories. If we consider the ...

Vivani Medical will spin off Cortigent, its neurostimulation business, as an independently publicly traded company as it looks to prioritise its portfolio of weight loss drug implants. While Vivani ...

We recently published a list of 10 Best Healthcare Stocks For Long-Term Investment. In this article, we are going to take a ...

neuromodulation devices, coronary stents, catheters, infant formula, nutritional liquids for adults, continuous glucose monitors, and immunoassays and point-of-care diagnostic equipment. Abbott ...

neuromodulation, structural heart, heart failure, rhythm management, and diabetes care. Several growth potentials are highlighted by Abbott Laboratories (NYSE:ABT)’s primary business.

The Vietnam baby food products market is projected to experience a steady growth rate, with a CAGR of 1.53% during the forecast period from 2025 to 2032. The market, valued at $1303.60 million in 2024 ...

Prior to joining Thermo Fisher, Tina led US and global commercial teams for the Diabetes Care and Rapid Diagnostics divisions of Abbott Laboratories ... a non-invasive neuromodulation company ...

The American Society of Pain and Neuroscience (ASPN) has just issued UPDATED guidelines for physicians using neuromodulation ...